The short－term and long －term clinical efficacy of aspirin combined with ticagrelor in the treatment of acute coronary syndrome patients with non－revascularization / 中国基层医药

ABSTRACT

Objective To explore the short－term and long－term clinical efficacy of aspirin combined with ticagrelor in the treatment of acute coronary syndrome ( ACS) patients with non －revascularization, to assess the improvement of cardiac function.Methods A total of 114 ACS patients with non －revascularization in Dajiang Hospital of Hangzhou were selected .They were randomly divided into control group and study group by random number table method,with 57 patients in each group.The control group was given aspirin and clopidogrel conventional therapy.The study group was treated with aspirin and ticagrelor .The clinical efficacy was evaluated .The Grace scores of ACS before and after treatment were evaluated ,and the serum levels of lactate dehydrogenase (LDH) and creatine phosphokinase(CPK) were measured.The patients were followed up for 12 months,the incidence of primary and secondary end points and the occurrence of dyspnea were observed .Results The total effective rate of the study group was 87.72%(50/57),which was higher than 71.93%(41/57) of the control group,the difference was statis－tically significant(χ2＝10.65,P＜0.05).The incidence rates of primary end point and secondary end point of the study group were 12.28%(7/57) and 17.54%(10/57),respectively,which were lower than 21.05%(12/57) and 35.09%(20/57) of the control group,the differences were statistically significant(χ2＝9.82,10.13,all P＜0.05). The incidence rate of dyspnea of the study group was 24.56%(14/157),which was higher than 3.51%(2/57) of the control group,the difference was statistically significant (χ2＝10.96,P＜0.05).The Grace score of the study group was (80.23 ±7.89)points,which was lower than (85.58 ±8.14) points of the control group,the difference was statistically significant(t＝9.38,P＜0.05).The levels of LDH and CPK of the study group were (217.06 ±44.34)U/L and (167.52 ±37.41)U/L,respectively,which were lower than (261.58 ±43.10)U/L and (225.48 ±38.26)U/L of the control group,the differences were statistically significant (t＝10.06,10.29,all P＜0.05).Conclusion Aspi－rin combined with ticagrelor for ACS patients with non －revascularization can effectively inhibit platelet aggregation , the clinical efficacy is significant ,the incidence of primary and secondary end points of patients with ACS was signifi －cantly reduced,the prognosis is good .While dyspnea rate increased ,but does not affect the treatment of patients .